Dr. Han is a geneticist interested in applying CRISPR/shRNA-based genetic screen tool to identify novel targets and synergistic drug combinations for cancer therapeutics. He developed CDKO, a novel CRISPR-based double-knockout screen platform that can measure pairwise genetic interactions and identify synergistic, selective drug combinations for cancer (Nat. Biotech., 2017). Since then, He has developed the first-ever genome-scale CRISPR screening platform in cancer organoids to identify cancer dependency with unprecedented accuracy (Accepted in Nature, 2020). Recently, He founded a biotech startup, MEDIC Life Sciences, to further develop and apply this cancer organoid screening platform for better cancer treatments and personalized medicine.